chrisvoncsefalvay/vaers-outcomes huggingface dataset:
received first dose of Pfizer Covid vaccine on 4Jan2021. She tested positive for covid a few days later; received first dose of Pfizer Covid vaccine on 4Jan2021. She tested positive for covid a few days later; This is a spontaneous report from a contactable consumer (patient's daughter). A female patient of an unspecified age received the first dose of BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE lot/batch number and expiration date not reported) via an unspecified route of administration on 04Jan2021 at a single dose for COVID-19 immunisation. The patient's medical history and concomitant medications were not reported. The patient received first dose of Pfizer COVID vaccine on 04Jan2021. She tested positive for COVID a few days later (2021) and was in rehab for a few months. Reporter calling to see if her mother can receive her second dose so late after the first one. Outcome of the event was unknown.  Information on the lot/batch number has been requested.
localized urticaria, immediate onset; responsive to diphenhydramine with recurrence next days. No systemic anaphylactic reaction on full review of systems by allergist 1/11/2021. Previous tolerance to annual flu immunizations, including FluLaval preservative free past 3 years.
Patient diagnosed with COVID on 9/17/22. Patient unable to provide any other vaccine information.
Minimal reactions after the first dose but after the second dose the left side of my neck has progressively become stiff and painful at times. This condition has persisted for months but only recently within the last month I started having very severe dizzy spells. While i never passed out there were a couple incidents where I felt a lot of pain and had to sit still for 30 minutes before I felt like I could safely get up and move about. It should be noted that I was in a car wreck 25 years ago and the left side of my neck was very sore and stiff for a long time, but physical therapy seemed to resolve the worst of that condition, with very minor discomfort after the PT.
This spontaneous case was reported by another health care professional and describes the occurrence of WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patient post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine administered to patient post temperature excursion) and NO ADVERSE EVENT (No adverse event) in an adult patient of an unknown gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. AR5186C) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patient post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine administered to patient post temperature excursion) and NO ADVERSE EVENT (No adverse event). At the time of the report, WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patient post temperature excursion), POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine administered to patient post temperature excursion) and NO ADVERSE EVENT (No adverse event) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered NO ADVERSE EVENT (No adverse event) to be not related. No further causality assessments were provided for WRONG PRODUCT ADMINISTERED (Pediatric dose was given to adults mistakenly), PRODUCT TEMPERATURE EXCURSION ISSUE (Moderna COVID-19 vaccine administered to patient post temperature excursion) and POOR QUALITY PRODUCT ADMINISTERED (Moderna COVID-19 vaccine administered to patient post temperature excursion).    Concomitant product use was not provided by the reporter.  It was reported there was a temperature excursion between 26-May-2022 to 30-Sep-2022 and lot AR5186C was affected between 08-Sep-2022 to 27-Sep-2022. AR5186C was previously reported. Pediatric dose was given to adults mistakenly and were reported to CDPH, VAERS, CAIR and each patient that received the error dose, with instructions to re-vaccinate 2 months from the initial error dose. 051B22A was kept in the freezer upon receipt of shipment on 01-Aug-2022 and individual vials were put in the refrigerator on the day of use.  No treatment information was provided.
Extremely sore arm to the point of not being able to lift more than 10 degrees without pain. Aches in many muscles in body that felt similar to flu-like symptoms. Very tired for about 24 hours.
I began to bleed very heavily about 2 days after the booster vaccination. I scheduled an appointment with doctor. I saw him about 3 days after. I was told by the doctor to stay home until it subside.
Patient gets a rash on the Torso, the rash starts to develop after 2 days of the vaccination, this happened after the 1st shot and she went to the ER, the ER provider said its too late for the shot to show up allergic reaction, so she did come and get the 2nd dose in the series. But, after two days of the shot she woke up again with a rash on her Torso, the rash is not progressing and is fading away now.
7/18/08 Noted to be breathing "funny" at home by parent- almost stops breathing-no color change; staring at times but no seizure spells. Injection site markedly swollen. Both parents reported that similar events happened to them as infants after DTaP shot.
my arm is still sore; This spontaneous case was reported by a consumer and describes the occurrence of PAIN IN EXTREMITY (my arm is still sore) in a 79-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 003B21A) for COVID-19 vaccination.     Concomitant products included CARVEDILOL, RIVAROXABAN (XARELTO), LISINOPRIL, POTASSIUM and BUMETANIDE for an unknown indication.   On 31-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) at an unspecified dose. On 31-Mar-2021, the patient experienced PAIN IN EXTREMITY (my arm is still sore). The patient was treated with PARACETAMOL (TYLENOL) at an unspecified dose and frequency. At the time of the report, PAIN IN EXTREMITY (my arm is still sore) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   Action taken with mRNA-123 is not applicable.
FLU SHOT GIVEN 4TH TIME AS CHILD HAS DUPLICATE GRITS ACCOUNT - ONLY 1 ACCOUNT WAS BEING UPDATED. FLU #1 - 10/01/2020 FLU#2 - 11/02/2020 FLU#3 - 12/02/2020 FLU#4 - 03/01/2021
Narrative:  Patient tested positive for COVID-19 and was hospitalized despite full vaccination of Moderna dose 1 and 2. Dose 2 on 03/10/2021, with no booster documented up to date.
Pt recvd vax & temp to 102.4; mom called MD began to have grunting type resp; took him to ER & temp had gone up to 103; CXR, bloodwork & spinal tap done, WBC Count was 23,000;
COVID-19 Pfizer BioNTech vaccine was administered to the patient on 05/05/2021 (incorrect diluent- sterile water for injection was used as diluent instead of preservative-free normal saline).  The patient had no symptoms. MD was notified of the error and the patient was monitored. The patient did not have any adverse event from receiving the vaccine.
Patient reports of dysuria and urinary burning after receipt of Moderna COVID19 Booster. Patient denies shortness of breath, chest pain/pressure, swelling, rash or hives, nausea/vomiting, diarrhea, or site reaction to injection site. Patient is adamant this is what caused her urinary tract infection for which she sought treatment for on 01/10/2022 in which she has been given nitrofurantoin 100mg PO BID x5 days and a urine culture has been sent.
itchy rash starting with shoulders, currently it is spreading to his legs. The doctor prescribed steroid cream and gave him an injection
I had a 7 month old come in for her 6 months vaccine. I was getting the vaccines ready and I grabbed a Hep B instead on a PREVNAR. The patient was also getting a DTaP, Hib and Rota.
Pt reported a red, splotchy area on upper arm from injection site and down approx. 6 inches, appearing 2 days after first dose of vaccination. Also complained of extreme soreness the day after. No itching, but warm to touch. Pt was unable to come to store, so area was only described over the phone. Advised to seek medical attention if worsening.
Brought to ER due to respiratory distress which was felt to be related to COVID. Patient's wife says that tested Covid for Covid 19 on 01/04/2022. His wife felt that he was not acting right starting Christmas Day. She said he was very fatigued and became more and more confused: He subsequently developed cough and fever.   The patient was admitted with the above concerns including respiratory faillure, acute kidney injury in the setting of renal transplant, and  confusion.   He was started on dexamethasone 6 mg IV.  The patient was placed on empiric. Zosyn and monitored in the ICU.  His oxygenation improved and he was down to 6L but he never regained full consciousness. Plans were made to continue treatment.  However the patent's kidney function continue to worsen and his mental status did not recover. On the evening of January 16 he developed apnea and became acutely pulseless.  Death was pronounced l/16/2.D22 on 1531 .
Pt t105 for 6 hrs; no other sx; Given APAP entire time;
Hives/ left arm, part of her outer knee area of her left leg, and back left side of neck broke out with little tiny hives; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP) from medical information team. The reporter is the patient.  A 57 year-old female patient received bnt162b2 (COMIRNATY), administered in arm left, administration date 03Nov2021 17:30 (Batch/Lot number: unknown) at the age of 57 years as dose 1, single for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported.  The following information was reported: URTICARIA (non-serious) with onset Nov2021, outcome "recovering", described as "Hives/ left arm, part of her outer knee area of her left leg, and back left side of neck broke out with little tiny hives".  Additional information: The caller confirms she was not a healthcare professional but she works at (Withheld) Pharmaceuticals. The caller was calling in regards to her COVID-19 vaccination, the first one. She mentions she had spoke with the lady who was going to give the caller her second vaccination and asked if she had heard anybody who broke out with hives after the vaccine. The caller explains her left arm and part of her outer knee area of her left leg broke out with little tiny hives. She also broke out on her arms. Within the last 5 days, she started getting hives on the back left side of her neck. Now, they are starting to go away. The caller asks if she can go ahead and get the second dose. She mentions her work gave her a deadline of 08Dec2021 to be fully vaccinated before they get rid of people. Healthcare Professional: Declined, stating she already spoke to her about it and her doctor said it probably could have been attributed to the vaccine, but she couldn't give a 100% confirmation. The caller clarifies she developed hives about a week after receiving the first dose, like 5 days after maybe. She confirms the hives are improving. She verifies she did have her vaccine record card but the person at (Withheld) took her card and she currently doesn't have it at the time of the call. Caller verifies she has not received her second dose yet.   No follow-up attempts are possible; information about lot/batch number cannot be obtained. No further information is expected.
Patient received a dose of the Moderna COVID-19 vaccine more than 12 hours after it was punctured; This spontaneous case was reported by a nurse and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Patient received a dose of the Moderna COVID-19 vaccine more than 12 hours after it was punctured) in a 72-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 071F21A and 071F21A) for COVID-19 vaccination.     No medical history was reported by the reporter.  Concomitant products included HYDROCHLOROTHIAZIDE, METFORMIN, SIMVASTATIN and LISINOPRIL for an unknown indication.   On 10-Nov-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 09-Dec-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 09-Dec-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Patient received a dose of the Moderna COVID-19 vaccine more than 12 hours after it was punctured). On 09-Dec-2021, EXPIRED PRODUCT ADMINISTERED (Patient received a dose of the Moderna COVID-19 vaccine more than 12 hours after it was punctured) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   Total amount of time the vial was exposed to room temperature range (8° to 25°C= 46° to 77°F). .4 hours at room temperature No treatment medications were reported.
Loss of taste; Loss of smell; This is a spontaneous report from a non-contactable consumer, the patient. A 43-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 02Apr2021 at 12:00 (at the age of 43-years-old) as a single dose for COVID-19 immunisation. Medical history and concomitant medication were not reported. The patient did not receive any other medications within two weeks prior to the vaccination. The patient had no allergies to medications, food or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 04Apr2021 at 13:30, the patient experienced loss of taste and loss of smell 49.5 hours after taking the vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the events. The clinical outcome of the events loss of taste and loss of smell was not resolved at the time of this report.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
now 2 hours later I have a rash on my belly; Metallic taste almost immediately; This is a spontaneous report from a contactable other healthcare professional (hcp).  A 46-years-old female patient received first dose BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, solution for injection, lot number EK9231, expiry date not reported), via an unspecified route of administration on 30Dec020 16:45 at a single dose in the left arm as Covid vaccine. The patient's medical history and concomitant medications were not reported.  The patient was not pregnant at the time of the vaccination. The patient previously took iodine and experienced allergies. The patient was not in other vaccine in four weeks. The patient had no prior COVID vaccination and was not tested for COVID post vaccination.  The patient experienced metallic taste almost immediately (30Dec2020 16:45) and now 2 hours (18:45) later patient have a rash on the belly. No treatments received in response to the events reported. The events reported as not serious (did not result in death, not life-threatening, did not cause/prolonged hospitalization, not disabling/incapacitating and not a congenital anomaly/birth defect. The events metallic taste and rash on the belly was not recovered.
1 day after vaccine given had redness and swelling at injection site an entire arm/fingers swollen; c/o insomnia past 2 nights.
Initial misuse report received from a healthcare professional on 23 September 2013. The cases were received on 21 March 2014 at GPV. A 03-year-old patient received 0.25 ml of FLUZONE. (No other information was provided regarding the patient). No adverse event was reported. List of documents held by sender: none
I have been having increased secretions and heavy mucous productions ever since reacting to the initial Covid vaccination. Initially secretions were noticed and  increased mucous shortly followed. This mucous and secretions have never been a normal for me and has been persistent since May.
Patient's mother yelled out that there was a problem. Ran out front with EpiPen in hand (not administered) to find him sitting on floor. Mother described how his eyes began to water & he seemed to go into what she described as a seizure. She said his arms & legs were shaking.  As we sat with him, he yawned a lot, said he was ready to go & felt ok. We put ice pack on back of his neck & gave him water. After about 10 minutes he stood & sat in a chair. With assistance of his mother & father he walked out.  Called around 4pm to check on him & he was in ER upon direction of his physician. Called around 6pm & was still in ER.
A 66-year-old female patient was in the observation area after her vaccination and began to itch in her right arm. The evaluation is carried out and consultation is made with Dr. and indicates that BENARYL 25mg PO be administered and left under observation for 30 minutes. Her vital signs were: 91 Pulse, 35.9C, 120/80 B/W, Breaths 15 and Dextrose 107.
Beginning on morning after vaccination, expected swelling, redness & itching began and lasted 5 days. On day after vaccination, I developed severe cramping in upper abdomen. This lasted 24 hours and, I feel was result of shot. 2 days after shot, I developed a severe cramp in same arm's forearm. Lasted 1 hour. Also there was slight nausea & dizziness. All gone now.
RED RAISED AREA 2 INCHES IN DIAMETER NO ITCHING SHE STATES FEELS WARM
approx 3-4 hrs p/ vax pt devel high pitched crying; cried for 1-2 hrs, unable to console; would stiffen during crying; would fall asleep while crying from exhaustion then high pitched crying would recur along w/stiffening of body; fever;
Information has been received from a medical assistant referring to a patient of unknown age and gender. The pertinent medical history and concomitant therapy of the patient were not reported. On an unspecified date in October 2015, the patient was vaccinated with the first dose of GARDASIL 9 (lot#, expiration date, dose and route were unspecified). On an unspecified date in July 2016, the patient was vaccinated with the second dose of GARDASIL 9 (lot#, expiration date, dose and route were unspecified). At the time of this report, the patient had not yet received the third dose. No adverse effects were reported. Additional information has been requested.
Severe chest pain. Lasting for an hour preceding the cessation of symptoms. Nearly went to hospital.
Giant hives on back, arms, legs shot of BENADRYL, prednisone in emergency room. Prescribed 5 day course of prednisone.
Pt seizured. Eyes rolled back, eyelids became puffy, pupils became dilated.
skin lesions; Based on the current case data, this case has been classified as invalid. This spontaneous case was reported by a consumer and describes the occurrence of SKIN LESION (skin lesions) in a patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced SKIN LESION (skin lesions). At the time of the report, SKIN LESION (skin lesions) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       No concomitant medications were mentioned. No treatment details were reported.
Chronic joint pain; This spontaneous case was reported by a consumer and describes the occurrence of ARTHRALGIA (Chronic joint pain) in a 65-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     taking an MAOI and pramipexzole Major depressive illness.  Concurrent medical conditions included Depressive illness (taking an MAOI and pramipexole  for Major depressive illness).    On 13-Mar-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 27-Mar-2021, the patient experienced ARTHRALGIA (Chronic joint pain). At the time of the report, ARTHRALGIA (Chronic joint pain) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular), the reporter did not provide any causality assessments.   No relevant concomitant medications were reported.  No treatment information was provided.   Most recent FOLLOW-UP information incorporated above includes: On 24-Jun-2021: Non-significant follow-up.
The day after receiving her flu shot. The patient noted the injection site was red, warm, tender, swollen. Site was examined and had a 5mmX10mm area of erythema, induration, and warmth.
Myalgia, Arthralgia, myalgias/arthralgias after 2nd dose resolved except t spine arthralgia has persisted>10d Narrative:
On the day of the vaccination the patient experienced blotchy skin on her face and neck. The following day the patient's right eyelid was swollen. The second day after vaccination, the patient's left eyelid was swollen. The patient was seen in urgent care and no treatment was needed.
sick; Initial information was received on 21-Nov-2020 regarding an unsolicited valid non-serious social media case from a consumer.  This case involves male patient (unknown age) who was sick (illness), while he received INFLUENZA VACCINE.  Medical history, medical treatment(s), concomitant medications, vaccination(s) and family history were not provided.  On an unknown date, the patient received a dose of suspect INFLUENZA VACCINE produced by unknown manufacturer (lot number and expiry date not reported) via an unknown route at an unknown administration site for prophylactic vaccination.  On an unknown date, the patient developed non-serious event, was sick (illness) (unknown latency) following the administration of INFLUENZA VACCINE.  Details of laboratory data were not reported.  It was not reported if the patient received any corrective treatment.  At the time of report, the outcome was unknown for the event.  There will be no information available on the batch number for this case.
Initial report received on 04 November 2008 from a consumer (coworker). A 40 to 45 year old female patient, whose medical history, concomitant medications, and illness at time of vaccination were unknown, received an injection of ADACEL (lot number UF455AA) on 29 October 2008. Two days later, on 31 October 2008, the patient had "a strange rash over 1/3 of body that looked like blotchy poison ivy". Corrective treatment included "a shot of steroids and maybe antibiotics". The patient's recovery status was unknown. No other information was known by the reporter.
Pt stated she felt dizzy.  B/P normal range, pulse rate lowered to 47.  Pt was monitored until pulse reate increased to 65.  Pt. was discharged home.
Narrative:  COVID infection following COVID vaccine series 05/01, Pfizer, dose #1 FACILITY 05/22, Pfizer, dose #2 FACILITY 1/2 COVID swab, result: detected 12/30 pt cc: severe body aches and cough exposure: unknown 1/02 CXR IMPRESSION: No acute cardiopulmonary disease 1/02 pt admit ED cc: severe body aches and cough dx: Covid 19 LOS: 1 day